(Sharecast News) - Ixico announced two new agreements worth a combined £1.2m on Wednesday, including a contract to support the validation of a diagnostic blood test and an extension to an existing Alzheimer's disease clinical trial.
The AIM-traded neuroscience analytics group said the new contract, signed with a leading global biopharma...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE